My Clinical Trial Locator: map
National Cancer Institute (NCI) Clinical Trials Search PDQ
NIH ClinicalTrials.gov Open Studies | Exclude Unknown | "Ovarian Neoplasms" with RSS feed link
Map of NCCN Member Institutions
- Stanford Clinical Trials (out of date), Ovarian/Peritoneal/Fallopian Cancer, Gynecologic Cancers, Solid Tumor, Gynecology Clinical Research Group Eligibility Flowcharts
, Phase 1 Clinical Research Program, Liquid biopsy
- UCSF Gynecologic Oncology Clinical Trials including upcoming, ovarian cancer list, solid tumors list, flow-chart, UCSF clinical trials, ovary search result, UCSF 500, Liquid biopsy
- UCSF Clinical Research Support Office Early Phase Clinical Trials Unit, Clinical and Translational Science Institute Early-Phase Clinical Trails Unit, Hematology and Oncology Research Earch Phase Initiative, Lab
- CPMC PAMF California Pacific Medical Center Gynecologic Cancer Clinical Trials
- UCLA
- City of Hope
- USC
Coalition of Cancer Cooperative Groups (Cancer Trials Help) Trial Screening Questionnaire, sorted by distance
EmergingMed creating profile
Cancer.net American Society of Clinical Oncology (ASCO) Finding a Clinical Trial information only
CenterWatch - Commercial clinical trials listing service institutional review board (IRB)-approved trials
NCI Cancer Trials Support Unit (CTSU) - NCI-sponsored phase III cancer treatment trials limited to some GOG, RTOG
* Alkylating antineoplastic agent - Carboplatin - crosslinking of DNA - crosslinking inhibit DNA repair and/or DNA synthesis - hypothermia enhances the effect
* Mitotic inhibitor - prevent/stop cell division - Taxane
- GOG-212 Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer PAMF
- Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial.
- History of Randomized Clinical Trials in Ovarian Cancer: Pre-Taxol Era, Taxol better for poorly-differentiated and late stage
- Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer resistance
- GOG-225 Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer SoCal
* HIPEC OVHIPEC info
- Surgery and Heated Chemotherapy for Adrenocortical Carcinoma NIH HC 4/12/2013
- ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis M S-K 3/13/2013-
+ Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer M S-K 1/10/2013
+ A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers Columbia 7/10/2012
- Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix MD A 4/17/2012-
- Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor MD A 1/12/2011
- Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer 2007 Phase III Netherlands
- Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment 2011 hase III France
- UC Irvine, Robert Bristow, Alessio Pigazzi, Kristine Penner
- UCSD, Andrew Lowy, Joel Baumgartner, Kaitlyn Kelly
Sharp, Robert Barone
Loma Linda, Maheswari Senthil
* Whole-body Hyperthermia
- Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (FR-WB-TT/che) UT HSC 9/13/2005
- Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer UT HSC 5/14/2004
- Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer UT HSC 12/10/1999
- Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer UTH 11/1/1999
* Recurring platinum sensitive
California Trials search
Califronia ovarian platinum Trials search, California Ovarian Recurrent search clinicaltrials.gov
* A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3), double blinded, Phase III, UCSF, PARP inhibitor
- Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer, phase I, Stanford
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), Part 2 for 3 prior chemo only, Phase II, UCSF, gBRCA
-
* Resistant, Refractory
closed Virus
** - Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies (BYL719 Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor), Phase Ib, UCSF
** - Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours Phase I, measurable, Wee1 p53 tp53, UCSF
** - A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Phase I, immune-resistant with taxol or platin, escalation, UCSF
* - Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Phase I, Flt3 mutation, CSF-1R inhibitor, with taxol, 2cm, UCSF
* - A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors Phase I, RAS MAPK mutation, Cleave, UCSF
** - Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors, liquid biopsy, Stanford
* - Phase I Trial of Hu5F9-G4, anti CD47 gene, escalation Stanford
Wee1: MK1775 3/26/2008, AZD1775 12/02/2012 PO
Chk1: Eli Lilly Prexasertib (LY2606368) IV NIH 4/28/2010
P53 Elephants' Cancer-Crushing Secrets May Someday Help People
Progress in p53-targeted drugs for ovarian cancer
Critical Outcomes Technologies Looks to Enter Clinical Race for p53 Drug to Treat Cancer
1. Cellceutix Corp CTIX Kevetrin (thioureidobutyronitrile), News, trials IV 8/2/2012
2. Aprea APR-246, trials IV 3/19/2014
3. Critical Outcome Technologies, Inc COT COTI-2, COTI2 vs Kevetrin, News, trials PO, MDA, NWU, 4/27/2015
* Anti Cancer Stem Cell CSC
Novogen: Cantrixil News
Other:
- CT Antigen TCR-redirected T Cells for Ovarian Cancer Phase I-II, HLA A2 tissue type, Stanford
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Phase I, ROS1/ALK mutation, escalation, Stanford
- NCI-Match, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas, 5/31/2016 Phase II, PTEN with PI3K, Stanford, PAMF, CPMC Afatinib, AZD9291 Crizofinib Dabrafenib Trastuzumab Defactinib Sunitinib, NCORP November 2015 Update, Lots of Enthusiasm in Initial Months
- A Phase 1/2 Study to Evaluate MEDI4736 Phase I-II, Stanford lung
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase I, failed standard treatments, Stanford not recruiting
- Study of ABT-165 in Subjects With Advanced Solid Tumors Phase I, UCD, Stanford breast
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies napabucasin Stemness Inhibitor Phase I, USC
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers Phase I, LA
- Phase 1 Study of CM-24 (MK-6018) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Phase I, LA
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Phase II, UCSF for lung
- LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Phase II, not in UCD
- A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Phase II, UCD phase II for Bladder/Urothelial Cancer
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Phase II, PARP-inhibitor, *Stanford*, CPMC-SF*
- Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR), ASCO (Michigan, Carolinas), Launched: Two of the Biggest Trials Yet for Precision Medicine
- A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (PISH-2) Phase I, Lilja, verthermia
- Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC) Phase II, CDDP, Lilja, BAGO
- PD-L1 Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), also search PDL1, PD-1, PD1, PD-L2, PDL2
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer (PemCiGem) phase 2, Cedar Sini
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 phase 1, Santa Monica
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Phase 2, LA
- Cediranib Maleate and Olaparib 1-prior PAMF
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Phase I,II,
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL) Phase III, PFI 1-6 months, no more 3, Stanford- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL), random Topotecan, 3 prior,
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), PARP Part 2 for 3 prior chemo only, Phase II, UCSF, Stanford
- Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer MET-inhibitor,
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
- GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Phase I, II, UCSF, not
+ Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
* Gemzar 1000mg/m^2 day1,8 + Carboplatin AUC 4 (Cisplatin 75mg/m^2) day 1 + Bevacizumab 15mg day 1 (A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)) Guidelines for Hospitalization for Chemotherapy outpatient
- 6-month chemo-free
.. PAMF trial
Metformin Hydrochloride Metformin is anti-diabetic medication to treat diabetes mellitus
- Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer - Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
- Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature
- Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule
- A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy 9/4/2012 San Francisco
IDO is an enzyme which causes deplition of tryptophan which causes halted growth of T-cells
How Our Immune System Can Help Fight Cancer (ovarian)
1. Incyte IDO1 A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy, A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma (not active A Dose-escalation Study in Subjects With Advanced Malignancies phase I)
2. IDO pathway inhibitor NewLink Genetics active: Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer, (terminated DO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT) phase I, paper Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer)
New perspectives on targeted therapy in ovarian cancer 2/2015
*Angiogenesis inhibitor
Bevacizumab 4/6/2000
-- Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer - targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib
-- Angiogenesis Foundation, videos
-- Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment OncLive list of clinical trials
- TRINOVA-2: Trebananib in Ovarian Cancer-2 with PLD, Phase III, San Francisco SF
- GOG-0213 with Gemcitabine
- nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
- A clinical experience of single agent bevacizumab in relapsing ovarian cancer 2013 The PFS tended to be better in patients who experienced grade 3-4 arterial hypertension during the first month of treatment (median: 10ms) compared to patients who did not (median: 3ms)
- Targeted anti-vascular therapies for ovarian cancer: current evidence 2013 Bevacizumab beyond progression
- Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer 2014 OCEANS trial
* Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer 2014
-1 Ovarian Cancer Subtypes May Predict Response to Bevacizumab - Prognostically relevant gene signatures of high-grade serous ovarian carcinoma - (proliferative, mesenchymal) > (immunoreactive, differentiated [CA125]) - Nature: Integrated genomic analyses of ovarian carcinoma
-2 Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab - AADx assay (Almac Group Ltd) - 3 subgroups (pro-angiogenic subgroups > immune response)
-A Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy (Bevacizumab)
- bevacizumab and hypertension avastin
- Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
- Treatment of bevacizumab-induced hypertension by amlodipine
- Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- Achieving better blood pressure control
- Isolated Diastolic Hypertension 2007, Isolated Diastolic Hypertension 1995 (no systolic hypertension)
- Seeking Alpha: Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
* PARP inhibitor for BRCA, PTEN
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Phase 2, UCSF
- Olaparib BRCA with chemo since 6/27/2007, Olaparib Maintenance Monotherapy in Patients With
* Trabectedin + Doxil
* Immunotherapy Vaccine
- Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy Phase II, III with mucin 1 gene, Stanford
- Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer Oregon
- Phase Ib Trial of Folate Binding Protein Vaccine in Ovarian Cancer Ease Coast
- Ovarian Cancer Vaccine for Patients in Remission Phase II, closed
* Antifolate
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) Phase III, Stanford, SF, suspended
Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer Phase II, NY
* Palliative
UHC
ECH, Palliative Care
PAMF, Palliative Care
Stanford Cancer Center Palliative Medicine Clinic
UCSF cancer symptom management
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options 2013
腹部腫脹, 食慾不振, 無法排便: 談婦癌病患的腸阻塞問題 bowel obstructionOvarian cancer Palliative care
** Pharmacologic Pearls for End-of-Life Care Morphine, Lorazepam, Compazine, Octreotide 0.3mg/day (papers), Levsin
* Malignant Bowel Obstruction Guide, bowel obstruction, edema, ascites, constipation: total parenteral nutrition TPN, gastrostomy, octreotide
* Fraser Health Hospice Palliative Care Symptom Guidelines for Nausea and Vomiting, dopamine D2, (Prochlorperazine [Compazine]) , 5-HT3 Ondansetron, Zophran, Hyoscyamine (Levsin)
Doctor, Does This Mean I'm Going to Starve to Death?
Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement
Palliative care in patients with ovarian cancer and bowel obstruction
Parenteral Nutrition in Malignant Bowel Obstruction: An Ethical Dilemma in Palliative Care
Gastrointestinal Complications
Palliative surgery for intestinal obstruction due to recurrent ovarian cancer
How Do You Triage Abdominal Pain in a Patient With Ovarian Cancer? small bowel obstruction SBO
Death Signs
** Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective, longitudinal cohort study nonreactive pupils, a decreased response to verbal stimuli, a decreased response to visual stimuli, an inability to close eyelids, drooping of the nasolabial fold, hyperextension of the neck, grunting of vocal cords, and upper gastrointestinal bleeding
*台灣文化中末期癌症病人臨終症狀之探討 Clinical signs and symptoms on end-of-life for terminally ill cancer patients in Taiwanese culture, 臨終症狀發生率由高至低依序為：發紺冰冷（98.3%），至死亡日平均3.4天；鏡面舌（93.4%），至死亡日平均8.5天；耳垂縮（93.4%），至死亡日平均5.6天；陳氏呼吸（91.7%），至死亡日平均0.53天；煩躁不安（78.5%），至死亡日平均7.7天；死前嘎嘎聲（Death rattle）（65.2%），至死亡日平均0.89天；陰莖（囊）縮（54.4％），至死亡日平均10.1天；末期躁動（37.1%），至死亡日平均9.9天；鞏膜水腫（33.1%），至死亡日平均10.1天；譫妄（28.9%），至死亡日平均9.4天；夢到過世親人（11.5%），至死亡日平均11.4天。
*Predicting Active Dying The median time until death following the death rattle was 57 (+ or - 23, SD) hours, 7.6 (2.5) hours following respiration with mandibular movement, 5.1 (1.0) hours following cyanosis, and 2.6 (1.0) hour following lack of radial pulse.
* Radiation Therapy
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase II, UCSF
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer Phase II, Germany
* Topoisomerase inhibitor
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Texas, NM
* BRCA
BRCA2 >> (BRCA1,none)
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.
* Bevacizumab completed or not recruiting
GOG-218 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2005, 22-course maintenance
GOG-252 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer 2009 dose-dense, 16-course maintenance
GOG-241 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer (mEOC/GOG-0241) 2010, 12-course maintenance
GOG-262 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2010
* Vascular Disrupting Agent (VDA) presentation
Zybrestat (Fosbretabulin tromethamine trial)
Bionomics BNC105 (BNC105P trial)
No comments:
Post a Comment